Allogeneic eye drops outperform autologous drops in treating dry eye symptoms in Sjögren’s syndrome

Allogeneic serum eye drops provide better relief from severe dry eye symptoms in patients with Sjögren’s syndrome (SS) compared to autologous serum eye drops, according to a study.

In the study, 5 patients with SS, who had used allogeneic serum eye drops for 5-28 months and autologous serum eye drops for at least 2 years, were analyzed. The assessment utilized Ocular Surface Disease Index (OSDI) scores and internal questionnaires to compare the efficacy of both treatments.

Results found that the mean OSDI score improved significantly with the use of allogeneic serum eye drops. The mean OSDI score dropped from 68.71 with autologous serum eye drops to 30.49 with allogeneic serum eye drops, suggesting that patients with SS experienced better symptom relief with allogeneic serum eye drops compared to autologous serum eye drops.

Reference
Janus J, Chmielewska K, Antoniewicz-Papis J. Allogeneic serum-based eye drops may give better results than autologous drops in Sjögren’s syndrome dry eye. Transfus Apher Sci. 2024;63(5):103991. doi: 10.1016/j.transci.2024.103991. Epub ahead of print. PMID: 39190936.

Related Content

• Ocular Surface Disease

Scleral lenses improve vision and symptoms across ocular surface diseases

• Dry Eye

Spotlight on LACRIFILL®

• Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

• Conference Roundup

If your patient has recurrent chalazia, consider co-occurring Demodex blepharitis

• Neurotrophic Keratitis

Novel anterior keratoplasty approach supports healing in refractory ocular surface disease

• Neurotrophic Keratitis

Shelf-stable amniotic membrane shows short- and long-term improvements in ocular surface disease